The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information
Identifieur interne : 000676 ( Istex/Corpus ); précédent : 000675; suivant : 000677The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information
Auteurs : Philip M. D. Wood ; Stephen J. ProctorSource :
- Leukemia Research [ 0145-2126 ] ; 1990.
English descriptors
- Teeft :
- Active compound, Acute disease, Acute gvhd, Allogeneic bone marrow transplantation, Allogeneic marrow transplantation, Bone marrow transplantation, Cell depletion, Chronic disease, Chronic gvhd, Cyclosporin, Donor marrow, Early stage, Graft, Gvhd, Immunosuppressive, Immunosuppressive actions, Lancet, Local lymph nodes, Lymphocyte, Marrow, Marrow transplantation, Methotrexate, Methyl prednisolone, Prophylactic agent, Prophylaxis, Queen victoria road, Royal victoria infirmary, Same system, Skin grafts, Skin homografts, Successful treatment, Surface receptor, Thalidomide, Thalidomide derivatives, Thalidomide metabolites, Thalidomide molecule, Thalidomide therapy, Transplant, Transplantation, University department, Vogelsang.
Abstract
Abstract: This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.
Url:
DOI: 10.1016/0145-2126(90)90024-4
Links to Exploration step
ISTEX:FD9EEE2DDA9371B6FD6BD981A5BDF8A6390CE334Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title><author><name sortKey="Wood, Philip M D" sort="Wood, Philip M D" uniqKey="Wood P" first="Philip M. D." last="Wood">Philip M. D. Wood</name><affiliation><mods:affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Proctor, Stephen J" sort="Proctor, Stephen J" uniqKey="Proctor S" first="Stephen J." last="Proctor">Stephen J. Proctor</name><affiliation><mods:affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FD9EEE2DDA9371B6FD6BD981A5BDF8A6390CE334</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/0145-2126(90)90024-4</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-3KSG3889-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000676</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000676</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title><author><name sortKey="Wood, Philip M D" sort="Wood, Philip M D" uniqKey="Wood P" first="Philip M. D." last="Wood">Philip M. D. Wood</name><affiliation><mods:affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</mods:affiliation></affiliation></author><author><name sortKey="Proctor, Stephen J" sort="Proctor, Stephen J" uniqKey="Proctor S" first="Stephen J." last="Proctor">Stephen J. Proctor</name><affiliation><mods:affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Leukemia Research</title><title level="j" type="abbrev">LR</title><idno type="ISSN">0145-2126</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="395">395</biblScope><biblScope unit="page" to="399">399</biblScope></imprint><idno type="ISSN">0145-2126</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0145-2126</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active compound</term><term>Acute disease</term><term>Acute gvhd</term><term>Allogeneic bone marrow transplantation</term><term>Allogeneic marrow transplantation</term><term>Bone marrow transplantation</term><term>Cell depletion</term><term>Chronic disease</term><term>Chronic gvhd</term><term>Cyclosporin</term><term>Donor marrow</term><term>Early stage</term><term>Graft</term><term>Gvhd</term><term>Immunosuppressive</term><term>Immunosuppressive actions</term><term>Lancet</term><term>Local lymph nodes</term><term>Lymphocyte</term><term>Marrow</term><term>Marrow transplantation</term><term>Methotrexate</term><term>Methyl prednisolone</term><term>Prophylactic agent</term><term>Prophylaxis</term><term>Queen victoria road</term><term>Royal victoria infirmary</term><term>Same system</term><term>Skin grafts</term><term>Skin homografts</term><term>Successful treatment</term><term>Surface receptor</term><term>Thalidomide</term><term>Thalidomide derivatives</term><term>Thalidomide metabolites</term><term>Thalidomide molecule</term><term>Thalidomide therapy</term><term>Transplant</term><term>Transplantation</term><term>University department</term><term>Vogelsang</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>thalidomide</json:string><json:string>gvhd</json:string><json:string>cyclosporin</json:string><json:string>transplantation</json:string><json:string>lancet</json:string><json:string>lymphocyte</json:string><json:string>vogelsang</json:string><json:string>methotrexate</json:string><json:string>prophylaxis</json:string><json:string>immunosuppressive</json:string><json:string>chronic gvhd</json:string><json:string>acute gvhd</json:string><json:string>graft</json:string><json:string>immunosuppressive actions</json:string><json:string>acute disease</json:string><json:string>chronic disease</json:string><json:string>marrow</json:string><json:string>prophylactic agent</json:string><json:string>methyl prednisolone</json:string><json:string>early stage</json:string><json:string>royal victoria infirmary</json:string><json:string>thalidomide therapy</json:string><json:string>skin grafts</json:string><json:string>thalidomide molecule</json:string><json:string>skin homografts</json:string><json:string>local lymph nodes</json:string><json:string>same system</json:string><json:string>thalidomide derivatives</json:string><json:string>thalidomide metabolites</json:string><json:string>active compound</json:string><json:string>surface receptor</json:string><json:string>queen victoria road</json:string><json:string>allogeneic bone marrow transplantation</json:string><json:string>allogeneic marrow transplantation</json:string><json:string>marrow transplantation</json:string><json:string>successful treatment</json:string><json:string>university department</json:string><json:string>donor marrow</json:string><json:string>cell depletion</json:string><json:string>bone marrow transplantation</json:string><json:string>transplant</json:string></teeft></keywords><author><json:item><name>Philip M.D. Wood</name><affiliations><json:string>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</json:string></affiliations></json:item><json:item><name>Stephen J. Proctor</name><affiliations><json:string>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Thalidomide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>graft-versus-host disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>GVHD : graft-versus-host disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>IL-2 : interleukin 2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mAbs : monoclonal antibodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MHC : major histocompatability complex</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MLC : mixed lymphocyte cultures</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PHA : phytohaemagglutinin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Con A : concanavalin A</value></json:item></subject><arkIstex>ark:/67375/6H6-3KSG3889-T</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Review article</json:string></originalGenre><abstract>Abstract: This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.</abstract><qualityIndicators><score>6.33</score><pdfWordCount>3358</pdfWordCount><pdfCharCount>19414</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>81</abstractWordCount><abstractCharCount>550</abstractCharCount><keywordCount>9</keywordCount></qualityIndicators><title>The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title><pmid><json:string>2189044</json:string></pmid><pii><json:string>0145-2126(90)90024-4</json:string></pii><genre><json:string>review-article</json:string></genre><serie><title>Transplantation Proc.</title><language><json:string>unknown</json:string></language><volume>19</volume><pages><first>2658</first></pages></serie><host><title>Leukemia Research</title><language><json:string>unknown</json:string></language><publicationDate>1990</publicationDate><issn><json:string>0145-2126</json:string></issn><pii><json:string>S0145-2126(00)X0147-6</json:string></pii><volume>14</volume><issue>5</issue><pages><first>395</first><last>399</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1953</json:string><json:string>1988</json:string><json:string>1990</json:string><json:string>1956</json:string></date><geogName></geogName><orgName><json:string>Leukaemia Research Fund</json:string><json:string>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary</json:string><json:string>D LABORATORY INFORMATION PHILIP M</json:string><json:string>University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Vogelsang</json:string><json:string>Two</json:string><json:string>S. J. Proctor</json:string><json:string>Proctor</json:string><json:string>A. Correspondence</json:string><json:string>Mrs Margaret</json:string><json:string>Sweden</json:string></persName><placeName><json:string>Germany</json:string><json:string>NE</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>Lim et al. [26]</json:string><json:string>[12]</json:string><json:string>[18]</json:string><json:string>[6]</json:string><json:string>Vogelsang et al. [21]</json:string><json:string>[22]</json:string><json:string>[8]</json:string><json:string>Coulson et al. [36]</json:string><json:string>[28]</json:string><json:string>Heit et al. [11]</json:string><json:string>[1]</json:string><json:string>Hellmann et al. [31]</json:string><json:string>[32]</json:string><json:string>Vogelsang et al. [23]</json:string><json:string>[38]</json:string><json:string>[3]</json:string><json:string>[20]</json:string><json:string>Vogelsang et al. [24]</json:string><json:string>[5]</json:string><json:string>[37]</json:string><json:string>[33, 34]</json:string><json:string>[7]</json:string><json:string>[25]</json:string><json:string>Saurat et al. [27]</json:string><json:string>[29, 30]</json:string><json:string>[2]</json:string><json:string>[35]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-3KSG3889-T</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - oncology</json:string><json:string>2 - hematology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - immunology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Cancer Research</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Oncology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1990</publicationDate><copyrightDate>1990</copyrightDate><doi><json:string>10.1016/0145-2126(90)90024-4</json:string></doi><id>FD9EEE2DDA9371B6FD6BD981A5BDF8A6390CE334</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3KSG3889-T/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3KSG3889-T/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-3KSG3889-T/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1990</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Review</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title><author xml:id="author-0000"><persName><forename type="first">Philip M.D.</forename><surname>Wood</surname></persName><affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Stephen J.</forename><surname>Proctor</surname></persName><note type="correspondence"><p>Correspondence to: Dr S. J. Proctor, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle-upon-Tyne, NE1 4LP, U.K.</p></note><affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</affiliation></author><idno type="istex">FD9EEE2DDA9371B6FD6BD981A5BDF8A6390CE334</idno><idno type="ark">ark:/67375/6H6-3KSG3889-T</idno><idno type="DOI">10.1016/0145-2126(90)90024-4</idno><idno type="PII">0145-2126(90)90024-4</idno></analytic><monogr><title level="j">Leukemia Research</title><title level="j" type="abbrev">LR</title><idno type="pISSN">0145-2126</idno><idno type="PII">S0145-2126(00)X0147-6</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="395">395</biblScope><biblScope unit="page" to="399">399</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1990</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Thalidomide</term></item><item><term>graft-versus-host disease</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>GVHD</term><term>graft-versus-host disease</term></item><item><term>IL-2</term><term>interleukin 2</term></item><item><term>mAbs</term><term>monoclonal antibodies</term></item><item><term>MHC</term><term>major histocompatability complex</term></item><item><term>MLC</term><term>mixed lymphocyte cultures</term></item><item><term>PHA</term><term>phytohaemagglutinin</term></item><item><term>Con A</term><term>concanavalin A</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1990">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3KSG3889-T/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="rev"><item-info><jid>LR</jid><aid>90900244</aid><ce:pii>0145-2126(90)90024-4</ce:pii><ce:doi>10.1016/0145-2126(90)90024-4</ce:doi><ce:copyright type="unknown" year="1990"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Review</ce:textfn></ce:dochead><ce:title>The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</ce:title><ce:author-group><ce:author><ce:given-name>Philip M.D.</ce:given-name><ce:surname>Wood</ce:surname></ce:author><ce:author><ce:given-name>Stephen J.</ce:given-name><ce:surname>Proctor</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Correspondence to: Dr S. J. Proctor, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle-upon-Tyne, NE1 4LP, U.K.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="11" month="12" year="1989"></ce:date-received><ce:date-accepted day="23" month="12" year="1989"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Thalidomide</ce:text></ce:keyword><ce:keyword><ce:text>graft-versus-host disease</ce:text></ce:keyword></ce:keywords><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text><ce:italic>GVHD</ce:italic></ce:text><ce:keyword><ce:text>graft-versus-host disease</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text><ce:italic>IL</ce:italic>-2</ce:text><ce:keyword><ce:text>interleukin 2</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text><ce:italic>mAbs</ce:italic></ce:text><ce:keyword><ce:text>monoclonal antibodies</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text><ce:italic>MHC</ce:italic></ce:text><ce:keyword><ce:text>major histocompatability complex</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text><ce:italic>MLC</ce:italic></ce:text><ce:keyword><ce:text>mixed lymphocyte cultures</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text><ce:italic>PHA</ce:italic></ce:text><ce:keyword><ce:text>phytohaemagglutinin</ce:text></ce:keyword></ce:keyword><ce:keyword><ce:text><ce:italic>Con A</ce:italic></ce:text><ce:keyword><ce:text>concanavalin <ce:italic>A</ce:italic></ce:text></ce:keyword></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information</title></titleInfo><name type="personal"><namePart type="given">Philip M.D.</namePart><namePart type="family">Wood</namePart><affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen J.</namePart><namePart type="family">Proctor</namePart><affiliation>Leukaemia Research Fund Remission Unit, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, U.K.</affiliation><description>Correspondence to: Dr S. J. Proctor, University Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle-upon-Tyne, NE1 4LP, U.K.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="Review article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1990</dateIssued><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.</abstract><note type="content">Section title: Review</note><subject><genre>Keywords</genre><topic>Thalidomide</topic><topic>graft-versus-host disease</topic></subject><subject><genre>Abbreviations</genre><topic>GVHD : graft-versus-host disease</topic><topic>IL-2 : interleukin 2</topic><topic>mAbs : monoclonal antibodies</topic><topic>MHC : major histocompatability complex</topic><topic>MLC : mixed lymphocyte cultures</topic><topic>PHA : phytohaemagglutinin</topic><topic>Con A : concanavalin A</topic></subject><relatedItem type="host"><titleInfo><title>Leukemia Research</title></titleInfo><titleInfo type="abbreviated"><title>LR</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1990</dateIssued></originInfo><identifier type="ISSN">0145-2126</identifier><identifier type="PII">S0145-2126(00)X0147-6</identifier><part><date>1990</date><detail type="volume"><number>14</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="issue-pages"><start>395</start><end>493</end></extent><extent unit="pages"><start>395</start><end>399</end></extent></part></relatedItem><identifier type="istex">FD9EEE2DDA9371B6FD6BD981A5BDF8A6390CE334</identifier><identifier type="ark">ark:/67375/6H6-3KSG3889-T</identifier><identifier type="DOI">10.1016/0145-2126(90)90024-4</identifier><identifier type="PII">0145-2126(90)90024-4</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-3KSG3889-T/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000676 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000676 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FD9EEE2DDA9371B6FD6BD981A5BDF8A6390CE334
|texte= The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information
}}
| This area was generated with Dilib version V0.6.33. |  |